ORIGINAL ARTICLE

ScienZTech

INTERNATIONAL RESEARCH JOURNAL OF PHARMACEUTICAL AND APPLIED SCIENCES

Published by ScienzTech Publication Journal Home Page: www.scienztech.org/irjpas

A Study of Chronic Liver Disease by Focusing Cardiovascular Changes

Arulanantham Zechariah Jebakumar*

Department of Vice Deanship of Post Graduate Studies and Research, Prince Sultan Military College of Health Sciences, Dhahran, Kingdom of Saudi Arabia.

Article History:

Received on: 06 Aug 2019
Revised on: 10 Sep 2019
Accepted on: 22 Sep 2019
Published on: 05 Oct 2019

Volume: 9 Issue: 3

Keywords:

Troponin I,
NT pro BNP,
Cirrhotic cardiomyopathy,
hyperdynamic and electrophysiological abnormalities

ABSTRACT

Cirrhotic cardiomyopathy can be explained as chronic dysfunction of the heart exhibited as blunted response to contractile function of the heart during Strain and decreased diastolic rest with odd electrophysiological (QT interval prolongation) adjustments, all taking region within the absence of an present cardiac disorder and irrespective of the reason of cirrhosis. Chronic Liver Disease is a process of revolutionary destruction and regeneration of the liver parenchyma leading to extensive spectrum of changes like persistent hepatitis, cirrhosis or hepatocellular carcinoma. Cirrhosis is one of the maximum common presentation of persistent liver sicknesses. It is characterized with the aid of reduced contractile responsiveness to stress, altered diastolic relaxation and electrophysiological abnormalities (QT interval prolongation) all happening within the absence of existing cardiac sickness. At gift there is evidence that, compromised liver feature and portal high blood pressure with splanchnic vasodilatation lead to the improvement of the hyperdynamic adjustments. Also other elements like increased sympathetic pastime, accelerated blood go with the flow and presence of arteriovenous communications can play extensive role in pathogenesis. Many pathophysiological mechanisms like decreased beta-receptor motion seem to be involved within the cardiac and autonomic disorder. Cirrhotic cardiomyopathy may be proven through tissue Doppler imaging and it's far quality tested with the aid of pharmacological or bodily strain. Diagnosis is done through 2D echocardiography, electrocardiography and cardiac serum markers (Troponin I, NT pro BNP). Elevation of troponin I is accepted to be a marker of cirrhotic cardiomyopathy. Troponin I proves to be a significant marker of myocardial injury in chronic liver disease patients. Although NT pro BNP is elevated as it can be elevated in fluid overload state related to liver disease it is unlikely to take it significant. The cardiovascular changes in the present study indicates that there was myocardial characterised by elevated troponin I.

*Corresponding Author

Name: Arulanantham Zechariah Jebakumar
Phone: 00966501098496
Email: zacbiostat@gmail.com

eISSN: 2277-4149

DOI: https://doi.org/10.26452/irjpas.v9i3.1260

Production and Hosted by

ScienzTech.org

INTRODUCTION

In this phase affords creation of this research work. The prevalence of cirrhosis is round four.Five% to nine.5 % of the general populace. [1, 2] The Global Health Observatory statistics has anticipated 39.5 deaths according to a hundred,000 populace and 19.6 deaths in step with one hundred,000 populations in women and men respectively (2014) in adults above 15 years (60). In India the burden of cirrhosis is 1,88,575 deaths (19.Four %) deaths from 1990 to 2010) as in keeping with 2010 GBD. [3,

4] Liver cirrhosis is related to intense hemodynamic changes that include hyperdynamic circulate with altered cardiac output, accelerated coronary heart price and reduced systemic vascular resistance. [5, 6] Cirrhotic cardiomyopathy is an entity mentioned in patients with advanced cirrhosis. Transplantation of the liver can also revert cardiac dysfunction but additionally surgical treatment and insertion of shunt may additionally worsen the impending heart condition. Also cirrhotic cardiomyopathy might lead to heart failure and to development of hepatic nephropathy after invasive approaches. [7, 8]

The prognosis of those patients is affected because of coronary heart failure, at some stage in invasive approaches which includes at some point of surgery, insertion of a transjugular intrahepatic portosystemic shunting and liver transplantation. [9, 10] Thus control of cirrhotic cardiomyopathy ought to observe the guidelines for the treatment of liver cirrhosis as well as for coronary heart failure. If beta-blockers do have any deleterious effect in this medical situation remains to be mounted. [9, 10]

In these articles represents sector 2 of these articles explains the feature on the related works. In section 3 presents the materials and methods adopted and section 4 presents the particulars of the experimentations and discussions. Finally segment 5 accomplishes the articles by allocation our implications and upcoming strategies.

RELATED WORKS

In this segment represents focuses the related works of this research work. Portal Hypertension is a common entity which results in a range of disorders like gastroesophageal varices, caput medusa, splenomegaly, hypersplenism. [11] The main pathophysiology involved in this can be explained by increased resistance and blood flow in the portovenous system. Ascites occurs due Ascites is a common complication due to amplified pressure in the hepatic vein. Complications of ascites is spontaneous bacterial peritonitis. [12] Hepatorenal syndrome occurs due to destruction in the renal blood flow. Hepatic encephalopathy when there is increased protein intake which is beyond the liver's capacity to metabolism.

Hepatopulmonary syndrome; porto-pulmonary hypertension are complications involving the respiratory system. The other co morbidities include malnutrition, coagulopathy due clotting factors deficiency, fibrinolysis, thrombocytopenia; bone disease- osteopenia, osteoporosis, osteomalacia; hematologic abnormalities – anemia, hemolysis, thrombocytopenia, and in some cases cirrhotic cardiomyopathy. [13]

Due to altered liver function and portal hypertension with systemic and splanchnic vasodilatation a hyperdynamic syndrome arises. Hyperdynamic syndrome is the hemodynamic parameter which relates the cardiac output (CO) from left ventricle in one minute to body surface area (BSA) thus relating the physic of the individual to the cardiac performance. [14, 15]

This hyperdynamic state is categorized by enlarged heart rate, cardiac output, reduced peripheral systemic confrontation and decreased or normal arterial pressure4. Also the systolic response of ventricle to stress is reduced. This results in blunted cardiac response to exercise. This is proved by experiments which have tested cirrhotic patients to stress. There is significant change in ejection fraction, chronotropic ineffectiveness, and reduced cardiac index. [16]

There is increased blood flow to the organs and reduced systemic arterial pressure leading to reduced arteriovenous oxygen difference due to which the quantity of circulating vasoactive substances such as vasoactive intestinal peptide, tumour necrosis factor- , glucagon, nitric oxide, endothelin-1, prostacyclin, and endothelin-3 that are activated by the liver are increased. (Figure 1 ,Table 1)

MATERIALS AND METHODS

In this segment represents the materials and methods of this research work. 50 adult patients identified with chronic liver disease were endangered to comprehensive history, examination, opening tests, specific investigations for cardiovascular system like cardiac markers (troponin I, CK MB, NT pro BNP), ECG and ECHO.

Institutional ethical committee clearance was obtained. Fifty patients diagnosed with chronic liver disease, who were admitted in the medical wards were taken into the study. Informed and written consent from the patients were obtained to participate in the study.

The patients were subjected to detailed history (age, sex, alcohol intake and duration of alcohol intake, duration of liver disease and co-existing conditions like Diabetes Mellitus and Hepatitis B, if any, were noted) and clinical examination (pallor, icterus, edema, splenomegaly, ascites and encephalopathy).

Table 1: Baseline investigations and the methods used

Investigation	Method
Liver function tests	
Total bilirubin	Jendrassik and Grof
Direct bilirubin	Jendrassik and Grof
AST	UV with P5P
ALT	UV with P5P
Total protein	Biuret
Albumin	BCG
Serum alkaline phosphatase	
GGT	GCNA
Coagulation parameters	
aPTT	Photo optical
PT	Photo optical
INR	Photo optical
Renal function test	
BUN	Urease
Serum creatinine	Jaffe Kinetic
HBsAg serology	ELISA
Electrolytes	
Sodium	ISE
Potassium	ISE



Figure 1: Cardiac Response

RESULTS AND DISCUSSION

In this phase focuses the results and discussions of this research work. In the existing have a look at of fifty topics, the suggest age become forty six.48 years, eighty four% topics have been male and sixteen% had been lady, those with tremendous history of alcohol consumption have been 68% and who did now not take alcohol were 32%. The Child Pugh and Meld scoring had been executed in these sufferers to evaluate the liver ailment severity and become as compared with the cardiac parameters (ECG, ECHO, cardiac markers). ECG and ECHO did now not show any tremendous adjustments. Troponin I became expanded in 24% of take a look at subjects compared with Child Pugh (P= 0.001) and MELD with average of 18 +/- 3 scoring (P= zero.0.5). NT pro BNP confirmed tremendous correlation whilst in comparison to Child Pugh categories 20 topics (40%) (P=0.001) and Meld scores with suggest of 17.19 +/- 3.9 showed positive (P=zero.022) which had been statistically widespread.

The second line investigations specific for cardiovascular system namely ECG (12 leads), Echo (2 dimensional) and cardiac markers are done using the methods mentioned in Table like troponin I done by CLIA method, in CK MB the IFCC method was used and NT pro BNP method of Fluorescence Immune Assay were taken.

CONCLUSION

Finally this work concludes, the abnormalities as indicated by earlier studies which had QTc prolongation as well as ejection fraction abnormalities by echocardiography. Based on this study it may be recommended that patient with chronic liver disease may need to be closely monitored for myocardial wound as there is a demonstrable rise in cardiac serum markers with cumulative harshness of liver disease.

FUNDING SUPPORT

None.

ACKNOWLEDGEMENT

The authors are thankful to all who have extended their constant support for the completion of the work.

Conflict of Interest

Authors declared no conflict of interest.

REFERENCES

[1] Bers DM. Calcium Cycling and Signaling in Cardiac Myocytes. Annual Review of Physiology. 2008;70(1):23–49. Available from: 10.1146/annurev.physiol.70.113006.100455.

[2] Gazawi H, Ljubuncic P, Cogan U, Hochgraff E, Ben-Shachar D, Bomzon A. The effects of bile acids on β-adrenoceptors, fluidity, and the extent of lipid peroxidation in rat cardiac membranes. Biochemical Pharmacology. 2000;59(12):1623–1628. Available from: 10.1016/s0006-2952(00)00259-8.

[3] Wang Z, Shi H, Wang H. Functional M3 muscarinic acetylcholine receptors in mammalian hearts. British journal of pharmacology; 2004.

[4] Brodde OE, Bruck H, Leineweber K, Seyfarth T. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Springer Science and Business Media LLC; 2001. Available from: 10.1007/s003950170003.

[5] Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic Nervous System and Heart Failure. Ovid Technologies (Wolters Kluwer Health); 2008. Available from: 10.1161/circulationaha.107.760405.

[6] Noma A. ATP-regulated K+ channels in cardiac muscle;.

[7] Ai X, Curran JW, Shannon TR, Bers DM, Pogwizd SM. Ca 2+ /Calmodulin–Dependent Protein Kinase Modulates Cardiac Ryanodine Receptor Phosphorylation and Sarcoplasmic Reticulum Ca 2+ Leak in Heart Failure. Ovid Technologies (Wolters Kluwer Health); 2005. Available from: 10.1161/01.res.0000194329.41863.89.

[8] Møller S, Bendtsen F, Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Informa UK Limited; 2001. Available from: 10.1080/00365510152567059.

[9] Hendrickson H, Chatterjee S, Cao S, Ruiz MM, Sessa WC, Shah V. Influence of caveolin on constitutively activated recombinant eNOS: insights into eNOS dysfunction in BDL rat liver. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2003;285(3):G652–G660. Available from: 10.1152/ajpgi.00143.2003.

[10] Bolognesi M, Sacerdoti D, Piva A, Pascoli MD, Zampieri F, Quarta S, et al. Carbon Monoxide-Mediated Activation of Large-Conductance Calcium-Activated Potassium

Channels Contributes to Mesenteric Vasodilatation in Cirrhotic Rats. Journal of Pharmacology and Experimental Therapeutics. 2007;321(1):187–194. Available from: 10.1124/jpet.106.116665.

[11] Council G, Assembly G. Global Burden Of Liver Disease: A True Burden on Health Sciences and Economies!!;.

[12] World Health Organisation. MORTALITY BURDEN OF DISEASE [internet].Global health obervatory data; 2012.

[13] Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al.. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC medicine; 2014.

[14] Pudil R, Pelouch R, Praus R, Vašatová M, Hůlek P. Heart failure in patients with liver cirrhosis. Czech Society of Cardiology; 2013. Available from: 10.1016/j.crvasa.2013.06.002.

[15] M Z, Aldo D, Giovanni A, Domenico M, Francesco P, Antonella A. New Therapeutic Approaches to Liver Fibrosis: A Practicable Route? Bentham Science Publishers Ltd.; 2008. Available from: 10.2174/092986708784911560.

[16] Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal Hypertension and Its Complications. Gastroenterology. 2008;134(6):1715–1728. Available from: 10.1053/j.gastro.2008.03.007.

ABOUT AUTHORS

Arulanantham Zechariah Jebakumar

Lecturer, Department of Vice Deanship of Post Graduate Studies and Research, Prince Sultan Military College of Health Sciences, Dhahran, Kingdom of Saudi Arabia.

Cite this article: Arulanantham Zechariah Jebakumar. **A Study of Chronic Liver Disease by Focusing Cardiovascular Changes**. Int. Res. J Pharm. App. Sci. 2019; 9(3): 26-30.

ScienZTech